Formulation and Characterization of Dispersible Tablets of Cefpodoxime Proxetil: A Cephalosporin Antibiotic

Author(s):  
Naveen Kumar ◽  
Prerna Sarup ◽  
Sonia Pahuja

The objective was to formulate rapid dispersible tablets of Cefpodoxime Proxetil using various types of superdisintegrants viz., Croscarmellose sodium (CCS), Sodium starch glycolate (SSG) and Crospovidone (CP) in varied concentrations (1-5%). The model drug for current investigation, Cefpodoxime Proxetil, a broad spectrum third generation Cephalosporin antibiotic belongs to BCS class IV. The preformulation studies were accomplished by determining the compatibility of model drug with respective excipients by FTIR studies. These studies, revealed no chemical interaction of excipients with the model drug. The formulation development was achieved in phases comprising of preliminary screening, pre-optimization and optimization studies. The bitter taste of model drug was masked by addition of flavors and sweeteners to make it pleasant for pediatric patients upon oral administration. The formulations (F1-F6) were prepared by direct compression method. The percent released from all formulations showed release of more than 90% of drug within 30 min with drug content of more than 95%. The study showed that formulation containing CCS as superdisintegrants furnished best results. Formulation F5 showed maximum (99.6%) drug release within 30 minutes which is prerequisite for dispersible tablets. It also possessed a rapid release of drug from the formulation. The F5 formulation showed comparative dissolution profile vis-a-vis a commercialized formulation. The study concluded that dispersible tablets of Cefpodoxime Proxetil can be an alternative to conventional dosage form for the treatment of urinary tract infection, skin infection, and upper respiratory tract infections.

INDIAN DRUGS ◽  
2016 ◽  
Vol 53 (10) ◽  
pp. 27-33
Author(s):  
B. P. Patel ◽  
◽  
D. M. Patel

Upper respiratory tract infections (URTIs) are illnesses caused by an acute infection which involves the upper respiratory tract: nose, sinuses, pharynx or larynx. Roxithromycin (macrolide antibiotic) and ambroxol HCl (mucolytic) are used for this treatment. The dual release system of roxythromycin and ambroxol HCl was successfully prepared by bi-layer tablet approach for management of URTI. Quick release of roxithromycin was achieved by using disintegrants and slow release of ambroxol HCl was achieved by using matrix formulation of drug with HPMC K4M and ethyl cellulose. The 32 full factorial design was adopted for optimization of polymer concentration to achieve identical drug release with theoretical dissolution profile. The amount of HPMC K4M and ethyl cellulose were selected as independent variable and the similarity factor with theoretical dissolution profile and percentage drug release at 10th hr was selected as dependent variables. The prepared dual release tablets were evaluated for physical parameters, drug content, in vitro drug release study, etc. All the parameters were found to be acceptable in range. As the concentration of HPMC K4M is increased, the drug release decreases and the effect of ethyl cellulose was found to be less compared to HPMC K4M.


Sign in / Sign up

Export Citation Format

Share Document